DrugPatentWatch Database Preview

MOVANTIK Drug Profile

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

When do Movantik patents expire, and when can generic versions of Movantik launch?

Movantik is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and two patent family members in thirty-seven countries.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

Summary for MOVANTIK

International Patents:	102
US Patents:	6
Applicants:	1
NDAs:	1
Suppliers / Packagers:	3
Clinical Trials:	10
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOVANTIK
DailyMed Link:	MOVANTIK at DailyMed

Pharmacology for MOVANTIK

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

US Patents and Regulatory Information for MOVANTIK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Pharms	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No
Astrazeneca Pharms	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No
Astrazeneca Pharms	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No			Y	Y
Astrazeneca Pharms	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes			Y	Y

  Purchase this report

or, see our see our flat-rate plans

Non-Orange Book US Patents for MOVANTIK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
2,015,197,470
8,349,307	Polymer conjugates of opioid antagonists
9,388,104	Chemically modified small molecules
8,034,825	Chemically modified small molecules

  Purchase this report

or, see our see our flat-rate plans

International Patents for MOVANTIK

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	03032990
Canada	2463938
Hungary	S1500026
World Intellectual Property Organization (WIPO)	2012044243

Supplementary Protection Certificates for MOVANTIK

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015 00028	Denmark		PRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141208
1694363/01	Switzerland		PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: SWISSMEDIC 65205 08.07.2015
2015000037	Germany		PRODUCT NAME: NALOXEGOL ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/962 20141208
2015019	Lithuania		PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: EU/1/14/962 20141208